Research projects

The ongoing projects are listed below.  The projects that have been completed and published are shown the Publications webpage.
 

  1. Global Analysis of Clinical Integrated Epidemiology Research for Small Cell Lung Cancer (GLACIERS). Lead: Geoffrey Liu, Nuria Zellweger, Rayjean Hung

  2. HLA functional analysis in lung cancer: Early-onset and never-smoking populations across ancestries. Lead: David Christiani, Xinan Wang

  3. Genetics of EGFR mutation. Leads: David Christiani, Xinan Wang

  4. Air pollution and lung cancer prognosis. Lead: Kiera Murison, Rayjean Hung

  5. Survival association analysis of lung cancer in LORD. Lead: Yohan Bosse

  6. GenExposomics and autophagy polygenic score. Lead: Baharia Mograbi, Chris Amos, Olga Gorlova

  7. ADH1B and ALHD SNP's and LC Risk. Lead: Ming-Tsang Wu

  8. Evaluating Sex Disparities in Lung Cancer Risk. Lead: Adam Reynolds, Chris Amos

  9. Smoking and Comorbidities on Lung Cancer Survival. Lead: Adrew Lam, Geoffrey Liu

  10. Genetic risk and menthol smoking. Lead: Stephanie Jones and Chris Amos

  11. Investigating the association between the genetically proxied effects of drugs targeting cardiometabolic traits and hormonal therapy and lung cancer survival. Leads: Tessa Bate, Philip Haycock, James Yarmolinksy

  12. Ancestry inference estimation methods to identify new susceptibility loci contributing to lung cancer. Leads: Hyeyeun Lim, Jinyoung Byun, Chris Amos

  13. Leveraging age-at-onset in multi-ethnic genome-wide association study to identify novel loci in lung cancer. Leads: Yafang Li, Chris Amos, Yohan Bosse

  14. Characterization of Extreme Phenotypes of Lung Cancer Risk. Leads: Jose Luis Perez-Gracia, Luis Montuenga

  15. Prognostic Factors for NSCLC by Stage. Leads: Geoffrey Liu

  16. Prognostic Factors for SCLC. Leads: Geoffrey Liu

  17. Identifying shared proteomic risk factor. Lead: James Yarmolinsky

  18. Develop multi-ancestry polygenic risk scores for lung cancer risk. Lead: Haoyu Zhang, Rayjean Hung, Xihong Lin, Chris Amos, Byun Jinyoung, Li-Shiun Chen, Laura Bierut

  19. The changing demographics and outcomes in older patients with lung cancer over time. Lead: Geoff Liu, Wei Xu, Elizabeth Faour, Shabbir Alibhai, Cathi Brown

  20. Impacts of long term smoking cessation and risk of lung cancer. Lead: James McKay, Lani Park, John Field, David Christiani, Chris Amos

  21. Identifying circulating proteins that are a causal consequence of genetic liability to poor prognosis using reverse MR. Leads: Philip Haycock, Rayjean Hung, Geoffrey Liu, Karl Smith-Byrne, James Yarmolinsky

  22. Characterization of genetic and epidemiologic architecture stratified by the stages of lung cancer in GWAS. Lead: Jinyoung Byun, Chris Amos

  23. Association of epidemiological and genetic variables with tumor size at diagnosis in non-small cell lung cancer. Lead: Olga Gorlova, Christopher Amos, Rayjean Hung

  24. Comprehensive investigation of lipidomics in lung cancer risk and prognosis. Lead: Beiwen Wu, Rayjean Hung, Geoffrey Liu, Chris Amos et al

  25. Cardiorespiratory fitness, physical activity, and sleep in relation to lung cancer risk using a Mendelian randomization approach. Lead: Eleanor Watts et al, NCI, Cambridge

  26. Evaluation of lung cancer PRS transferability from the perspective of uncertainty in individual PRS. Lead: Xinan Wang, David Christiani, Xihong Lin et al

  27. Reliable PRS estimation improves the prediction performance of lung cancer risk. Lead: Xinan Wang, David Christiani, Xihong Lin et al

  28. Using germline risk variants to understand interactions between cancer and the immune system. Lead: Xin He, Rayjean Hung, Aida Ferreiro et al

  29. Identifying germline risk variants to understand risk of lung cancer and smoking cessation measures in former smokers. Lead: Lani Park et al

  30. The association of blood protein biomarkers with lung cancer incidence and survival: a joint Mendelian Randomization and nested case-control study. Lead: Karl Smith Byrne, Mattias Johansson et al

  31. Examining the genetic overlap of tobacco use, cannabis use and use disorder, and lung cancer. Lead: Arpana Agrawal, Laura Beirut et al

  32. Genetic landscape analysis of short tandem repeats on the risk and survival of lung cancer. Lead: Mulong Du, David Christiani

  33. Mendelian randomization studies of sleep traits and lung cancer risk. Lead: Brigid Lynch, Suzanne Dizon-Suen, James McKay et al

  34. Circulating vitamin E levels and multiple cancers risk: A Mendelian randomization analysis. Lead: David Christiani et al

  35. Machine learning methods to identify genetic variants and risk factors that discriminate between never smoking cases and controls. Lead: Monica Reyes, Matthew Schabath et al

  36. Investigating the causal role of genetic variation in white blood cell traits in lung cancer etiology and prognosis. Lead: Linda Kachuri, Rayjean Hung

  37. LD Score Analysis of Lung Cancer using Multi-Traits from UK Biobank. Lead: Jacob Edelson, Chris Amos et al

  38. Evaluating genetic, clinical, and environmental risk factors for second primary lung cancer. Lead: Summer Han

  39. Genetic architecture of lung cancer using machine-learning approaches in genome-wide association studies. Lead: Jinyoung Byun, Chris Amos

  40. Genes related to Genetic And Rare lung Diseases (GARD) as risk for LC. Lead: Albert Rosenberg

  41. Appraising the causal relevance of DNA methylation in lung cancer through two-sample Mendelian randomization. Lead: Rebecca Richmond, Caroline Relton et al

  42. Genetic contributions to lung cancer risk conveyed through inflammatory and immune pathways. Lead: David Christiani

  43. Genetic variant associated with mosaic chromosome alterations. Lead: Chao Cheng, Christopher Amos, James McKay

  44. Mendelian randomization study of circulatory microRNAs and risk of lung cancer. Lead: Kostas Tsilidis, Sarah Chen, Rima Mustafa, Marina Evangelou, Mohsen Ghanbari, Rayjean Hung, Abbas Dehghan

  45. Mendelian randomization study of allometric anthropometric indices and risk of lung cancer. Lead: Sofia Christakoudi, Emmanouil Bouras, Eleni Boutsikari, Chris Amos, Kostas Tsilidis

  46. Identifying germline risk variants to understand risk of lung cancer and smoking cessation measures in former smokers. Lead: S. Lani Park, L. Le Marchand, D. Stram, C. Amos, J. McKay

  47. Detecting racial disparities in cancer survival by integrating multiple high-dimensional observational studies. Lead: Y. Li, S. Guha, D. Christiani

  48. Illicit drug abuse (opium, cocaine, crack cocaine, phencyclidine, etc.) and lung cancer risk and survival. Lead: M. Zhang, Z. Zhang, R. Hung, P. Boffetta

  49. Machine learning methods to identify genetic variants and risk factors that discriminate between never smoking cases and controls. Lead: Monica E. Reyes, Matthew B. Schabath, Travis Gerke, Zuo-Feng Zhang, Qing Lan, Rayjean Hung, Olga Y. Gorlova

  50. Vitamin D and lung cancer survival: a Mendelian randomization study. Lead: Mei Jiang, David Christiani, Rayjean Hung, Geoffrey Liu, Wei Xu

  51. Mendelian Randomization Study of BMI, and the Moderating Effects on Inflammation, on Survival of Lung Cancer. Lead: Mei Jiang, Rayjean Hung, Chris Amos, Wen Zhou, Geoffrey Liu, Wei Xu

  52. Evaluating change in BMI as a predictor for lung cancer risk. Lead: Wen Zhou, Geoffrey Liu, Quinn Ostrum, Jinyoung Byun, Younghun Han, Paul Brennan, Rayjean Hung, Chris Amos

  53. Clinical predictors for EGFR mutation in Lung Cancer. Lead: Geoffrey Liu et al

  54. Epigenome-wide survival analysis. Lead: D. Christiani

  55. Clinical outcome based on Exome sequencing. Lead: R. Zhang, D. Christiani et al

  56. Molecular overlap between COPD and lung cancer. Lead: M. Obeidat

  57. Genome-wide Association Study of Small Cell Lung Cancer. Lead: Jyoti Malhotra, Paolo Boffetta, David Christiani

  58. Identification of interacting genetics associated with early age at diagnosis in lung adenocarcinoma. Lead: L. Briollais

  59. Tobacco specific constituents and lung cancer risk. Lead: Zuo-Feng Zhang

  60. Somatic and genomic analysis. Lead: Chris Amos

  61. Disease prediction from GWA data - utilising prior information of pathway analysis. Lead: Rayjean Hung, Nilanjan Chatterjie et al

  62. Risk variant generalizability and effect modification. Lead: Loic Le Marchand et al